Abstract
The treatment of disseminated melanoma is inadequate. The most active single agents provide brief objective response in 20% of patients, while the combination chemotherapy improves response rates without any apparent survival benefit. Median overall survival is, in fact, 7-9 months and 5 year survival is approximately 6%. Metastatic melanoma with a localization of the disease in the liver and brain are categorized as M1c and have the worst prognosis. Here we describe the history, treatment and favourable clinical outcome in a young man with liver and resected brain metastases who obtained complete remission for 6 years since chemotherapy with dacarbazine, cisplatin and vinblastine.
| Original language | English |
|---|---|
| Pages (from-to) | 1429-1431 |
| Number of pages | 3 |
| Journal | Anticancer Research |
| Volume | 28 |
| Issue number | 2 B |
| Publication status | Published - Mar 2008 |
Keywords
- Long-term survival
- Melanoma
- Metastatic disease
ASJC Scopus subject areas
- Cancer Research
- Oncology
Fingerprint Dive into the research topics of 'Unexpected clinical outcome in a patient with liver and brain metastasis from melanoma'. Together they form a unique fingerprint.
Cite this
Nuzzo, C., Zeuli, M., Ferraresi, V., Ciccarese, M., Pelligrini, D., & Cognetti, F. (2008). Unexpected clinical outcome in a patient with liver and brain metastasis from melanoma. Anticancer Research, 28(2 B), 1429-1431.